Cargando…
Efficacy of Prolonged-Release Melatonin 2 mg (PRM 2 mg) Prescribed for Insomnia in Hospitalized Patients for COVID-19: A Retrospective Observational Study
Background: we have observed the effect of insomnia treatment in clinical and prognostic differences of patients admitted for COVID-19 pneumonia in respiratory sub-intensive units that were administered a prolonged-release melatonin 2 mg (PRM 2 mg) therapy versus a group of patients out of therapy....
Autores principales: | Bologna, Carolina, Madonna, Pasquale, Pone, Eduardo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705392/ https://www.ncbi.nlm.nih.gov/pubmed/34945156 http://dx.doi.org/10.3390/jcm10245857 |
Ejemplares similares
-
Experimentally Observed Nucleation and Growth Behavior of Mg/MgH(2) during De/Hydrogenation of MgH(2)/Mg: A Review
por: Lyu, Jinzhe, et al.
Publicado: (2022) -
Prolonged-release melatonin for insomnia – an open-label long-term study of efficacy, safety, and withdrawal
por: Lemoine, Patrick, et al.
Publicado: (2011) -
New approaches in the management of insomnia: weighing the advantages of prolonged-release melatonin and synthetic melatoninergic agonists
por: Hardeland, Rüdiger
Publicado: (2009) -
Long-Term Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children with Autism Spectrum Disorder
por: Maras, Athanasios, et al.
Publicado: (2018) -
Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention
por: Gonçalves, Andre Leite, et al.
Publicado: (2016)